New cancer drug FH-006 enters human trials for solid tumors

NCT ID NCT06735144

Recruiting now Disease control Sponsor: Jiangsu HengRui Medicine Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests an experimental drug called FH-006 in 200 people with advanced solid tumors that have not responded to standard treatments. The goal is to check the drug's safety, find the best dose, and see if it can shrink tumors. Participants receive FH-006 by IV every 2 or 3 weeks.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: FH-006 (an experimental drug given by IV)
What this could lead to: If successful, this could point toward a new treatment option for people with advanced solid tumors who have run out of standard therapies.
What could go wrong: This is an early-phase trial (Phase 1/2) with only 200 participants, so the drug may not work or could have serious side effects. It is not yet proven to be safe or effective.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MALIGNANT SOLID TUMOR are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MALIGNANT SOLID TUMOR

Contacts and locations

Locations

Sun Yat-sen University Cancer Center
RECRUITING

Guangzhou, Guangdong, 510060, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.